{"id":7078,"date":"2025-06-12T08:58:38","date_gmt":"2025-06-12T08:58:38","guid":{"rendered":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/?page_id=7078"},"modified":"2025-11-17T19:09:52","modified_gmt":"2025-11-17T19:09:52","slug":"pku-management","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/pku-management\/","title":{"rendered":"Challenges in PKU"},"content":{"rendered":"
Lack of access<\/strong> to or affordability of medical foods\/formula and low-protein foods1<\/sup><\/p>\n <\/div>\n <\/div>\n Lack of caregiver support<\/strong>, especially as patients transition from adolescence to independent adulthood1<\/sup><\/p>\n <\/div>\n <\/div>\n Time<\/strong> it takes to plan and prepare Phe-restricted meals1<\/sup><\/p>\n <\/div>\n <\/div>\n Social impact<\/strong> of a Phe-restricted diet, including challenges with socialization and feelings of isolation1<\/sup><\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n FDA-approved BH4 therapies vary in effectiveness based on continual adherence to a Phe-restricted diet.2<\/sup><\/p>\n <\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n![]()
![]()
![]()
BH4 therapies are not an option for some adults with classical PKU1,2<\/sup><\/h2>\n <\/div>\n\n
\t\t\t<\/div>\n\t\t\t
\t\t\t<\/div>\n <\/div>\n <\/figure>\n\nChallenges will continue to exist for therapies or management approaches that require a long-term restricted diet.2<\/sup>\n<\/h2>\n \t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n <\/div>\n <\/div>\n